SELB News and Press, Selecta Biosciences Inc.

2023-11-13 08:41:26 ET More on Selecta Biosciences Selecta Biosciences GAAP EPS of -$0.07 beats by $0.01, revenue of $5.2M misses by $5.89M Seeking Alpha’s Quant Rating on Selecta Biosciences Historical earnings data for Selecta Biosciences Financial i...

– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been ...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Selecta Biosciences Inc. (SELB) is expected to report $-0.06 for Q3 2023

2023-11-01 08:51:55 ET Losers: WeWork ( WE ) -40% . Paycom Software ( PAYC ) -38% after Q3 earning release . IRIDEX Corp. ( IRIX ) -15% . Silicon Laboratories ( SLAB ) -26% after Q3 earning release . Extreme Networks ( EXTR )...

WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it has entered i...

2023-10-25 17:46:04 ET More on Selecta Biosciences Selecta Biosciences GAAP EPS of -$0.07 beats by $0.01, revenue of $5.2M misses by $5.89M Seeking Alpha’s Quant Rating on Selecta Biosciences Historical earnings data for Selecta Biosciences Financial i...

2023-08-17 07:58:15 ET More on Selecta Biosciences Selecta surges ~20% as gout drug SEL-212 meets main goal in 2 phase 3 trials Selecta Biosciences stock rises 10% on license deal with Astellas for Xork For further details see: Selecta Biosciences GAAP EPS of -$0...

– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licen...

2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...